Yet, given that glucagon modulates insulin release [20], [21], the potential contribution of altered glucagon levels to the β-cell hypersecretion and hyperinsulinemia of GC-treated subjects remains to be investigated. The gene discussed is INS; the disease is hyperinsulinism.